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ABSTRACT 
Chronic inflammation, induced by the use of tobacco and alcohol, or caused by infections 
has long been suggested to constitute a risk factor for head and neck squamous cell 
carcinoma (HNSCC). The innate immunity is the first line of defense against pathogens, 
comprising physical and chemical barriers, anti-microbial peptides, pattern-recognition 
receptors (PRRs) as well as different kinds of cells, including neutrophils. Among the 
PRRs, Toll-like receptors (TLRs) and Nucleotide oligomerization domain (Nod)-like 
receptors (NLRs) have gained much attention. They both recognize viruses and bacteria. 
In addition to their protective role against infections, accumulating evidence suggests a 
role for these receptors in cancer. Neutrophils are among the first cells to migrate into an 
inflamed tissue, and their role in various infections is well described. Several studies have 
demonstrated anti-tumor activities of these cells, but they are also believed to have a 
tumor-promoting role. Recent data indicate the existence of three distinct neutrophil 
subsets, CD16dim CD62Lhigh, CD16high CD62Lhigh, and CD16high CD62Ldim cells, with 
diverse roles in infection, inflammation and cancer. The overall aim with this thesis was to 
investigate the potential role of PRRs and neutrophils in HNSCC.  
The thesis demonstrated that the HNSCC cells exhibited high levels of TLR2, TLR3, and 
TLR5, and a diverse NLR expression. Stimulation of TLR2, TLR3, TLR5, and Nod1 
induced a robust inflammatory response and cell death in HNSCC cells that differed from 
what was seen in corresponding healthy epithelial cells. Following PRR stimulation the 
cancer cells up-regulated their expression of ICAM-1, and TLR activation increased the 
secretion of IL-1β, IL-6, and IL-8. In contrast, Nod1 enhanced the production of G-CSF 
and GM-CSF in HNSCC cells. In addition, the TLRs also affected the survival of the 
malignant cells. Altogether, this strengthens the suggestion that PRRs might mediate 
receptor specific tumor effects that can be either anti- or pro-tumorigenic. In the present 
study of HNSCC, TLRs induced an anti-tumorigenic response, whereas Nod1 activation 
caused pro-tumorigenic effects.  
Generally, HNSCC patients had a higher level of leukocytes and specifically more 
neutrophils in blood than healthy controls. Consequently, the neutrophil/lymphocyte 
ratio was high in the cancer patients, and a high ratio predicted worse prognosis. The 
three different neutrophil subsets mentioned above were found in the circulation of 
patients with HNSCC. The cancer patients exhibited a higher percentage of CD16high 
CD62Ldim cells than the healthy controls. Among the HNSCC patients, individuals with a 
high percentage of CD16high CD62Ldim neutrophils had a better outcome. In addition, the 
CD16high CD62Ldim cells represented the most active neutrophil phenotype. Hence, it 
might be that these activated neutrophils have anti-tumorigenic properties, and therefore 
are more favorable for the survival of the HNSCC patients. Altogether this emphasizes 
6 
 
the beneficence of having an ongoing process of neutrophil recruitment and activation in 
patients with HNSCC. 
Patients with allergic rhinitis (AR) and HNSCC were found to exhibit distinct 
immunological reactions. The allergic patients exhibited enhanced serum levels of both 
Th1 and Th2 cytokines. The same increase was also seen in supernatants from their 
cultured PBMC. In contrast, HNSCC patients had an increase in serum level of cytokines 
reflecting an innate immune reaction. PMN isolated from these patients showed a 
generally increased basal activation, and responded strongly to TLR stimulation. Further, 
tumor biopsies from HNSCC patients displayed a higher Nod2 mRNA expression than 
nasal biopsies from healthy controls and AR patients outside and during pollen season. 
All in all, the immune reaction among the allergic patients had an adaptive character with 
an enhanced T cell activity, whereas the immune reaction of the HNSCC patients was 
dominated by an innate immune response with suppressed T cells. It is therefore 
tempting to propose that the enhanced systemic adaptive immune response seen among 
patients with AR might protect against development of HNSCC. 
In summary, this thesis demonstrates a receptor specific expression and function of PRRs 
in HNSCC. It also reveals that the inflammation in HNSCC is dominated by innate 
immune activities, and that recruitment and activation of neutrophils is important for the 
survival of these patients. Consequently, the ability to muster a proper inflammatory 
reaction might be vital for the defense and survival in patient with HNSCC. 
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POPULÄRVETENSKAPLIG SAMMANFATTNING 
Huvud- halscancer är den sjätte vanligaste cancerformen i världen och består 
huvudsakligen av tumörer i de övre luftvägarna. Kronisk inflammation framkallad av 
tobak, alkohol och infektioner anses vara en bidragande orsak till dess uppkomst och 
utveckling. Målet med föreliggande avhandling är att undersöka betydelsen av så kallade 
patogen-igenkännande receptorer (PRRs) och neutrofiler i detta utvecklingsförlopp. 
Immunförsvaret kan förenklat delas in i ett adaptivt och ett medfött immunförsvar. Det 
medfödda försvaret är snabbt och ospecifikt och utgörs bland annat av PRRs och 
neutrofiler. PRRs känner igen invaderande bakterier och virus och består till exempel av 
toll-lika (TLRs) och nod-lika receptorer (NLRs). När de känner igen en främmande 
mikroorganism framkallar dessa receptorer ett inflammatoriskt svar vars primära roll är att 
bekämpa inkräktaren och därmed skydda mot infektioner. Det har dock visat sig att 
felaktig eller långdragen kontinuerlig aktivering samt mutationer i PRR gener kan ge 
upphov till cancer  
I avhandlingens första del undersöktes TLRs och NLRs uttryck och funktion i huvud- 
halscancer. Uttrycket av TLRs och NLRs i cancercellerna skiljde sig påtagligt från 
uttrycket i de friska cellerna. Aktivering av TLRs och NLRs gav i cancercellerna upphov 
till ett starkt inflammatoriskt svar, medan nästan ingen effekt sågs hos de friska 
kontrollcellerna. Dessutom förkortade TLR stimulering cancercellernas livslängd. 
Kortfattat kan man säga att TLR aktivering gav en antitumerogen effekt, medan NLR 
framkallade ett inflammatoriskt svar som närmast främjade cancerns utveckling. 
Följaktligen uppvisar PRRs en receptorspecifik påverkan på huvud- halstumörer. 
Neutrofiler är viktiga för att bekämpa och ta död på inkräktande mikrober. De migrerar 
tidigt ut i inflammerad vävnad med målet att ta död på bakterier. På senare tid har 
neutrofiler även visat sig ha andra funktioner. Bland annat tycks de ha en betydande roll 
vid utvecklingen av tumörer, men har även visats motverka cancerns utveckling. Kanske 
kan en del av förklaringen till dessa motstridiga funktioner ha sin grund i att man nyligen 
upptäckt olika subpopulationer av neutrofiler som uppför sig på skilda sätt vid infektion 
och inflammation. Man talar om tre olika grupper CD16dim CD62Lhigh, CD16high 
CD62Lhigh och CD16high CD62Ldim celler.  
Avhandlingens andra del fokuserar på neutrofilernas roll vid huvud- halscancer. 
Cancerpatienterna visades ha en högre andel neutrofiler i blodet än friska 
kontrollpatienter och de tre neutrofilpopulationer som beskrevs ovan återfanns i blodet 
från cancerpatienterna. Cancerpatienter med hög andel CD16high CD62Ldim celler hade en 
klart bättre överlevnad. Dessutom uppvisade de CD16high CD62Ldim neutrofilerna en 
aktiverad profil. Dessa resultat tyder på att en ökad andel CD16high CD62Ldim celler kan 
8 
 
tolkas som ett tecken på en ökad neutrofil aktivering som troligen bidrar till att hålla 
cancern i schack.  
Under flera år har det debatterats huruvida det finns något samband mellan allergi och 
cancer. Diskussionen har främst baserats på epidemiologiska studier och slutsatserna 
skiljer sig åt. I avhandlingens avslutande arbete studerades likheter och skillnader i det 
immunologiska svaret vid huvud- halscancer och pågående pollenallergi. Tillstånden kan 
ses som representanter för var sin form av kronisk inflammation inom 
huvudhalsområdet. Den allergiska reaktionen karakteriserades av ett adaptivt svar, medan 
det medfödda försvaret dominerade vid tumörsjukdomen. Dessa resultat stödjer den 
tidigare framförda tanken om att ett överaktivt adaptivt försvar hos patienter med 
allergisk rinit kan skydda mot utvecklingen av huvud- halscancer.   
Sammantaget belyser denna avhandling betydelsen av PRRs och dess förändrade uttryck 
och funktion i huvud- halscancer. Dessutom åskådliggörs vikten av neutrofiler och 
neutrofil framkallad inflammation hos patienter med huvud- halscancer. Avhandlingen 
betonar betydelsen av det medfödda immunförsvaret som ett skydd mot cancer.  
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ABBREVIATIONS 
ANXV Annexin V 
AR Allergic rhinitis 
CD Cluster of differentiation 
CT Cycle treshold 
ELISA Enzyme-linked immunosorbent assay 
FSc Forward scatter 
G-CSF Granulocyte-colony stimulating factor 
GM-CSF Granulocyte monocyte-colony stimulating factor 
HNEC Human nasal epithelial cells 
HNSCC Head and neck squamous cell carcinoma 
HPV Human papillomavirus 
ICAM-1 Intercellular adhesion molecule-1 
iE-DAP γ-D-glutamyl-meso-diaminopimelic acid 
IFN Interferon 
Ig Immunoglobulin 
IL Interleukin 
LPS Lipopolysaccharide 
MCP-1 Monocyte chemotactic protein-1 
MIP-1β Macrophage inflammatory protein-1β 
Naip Neuronal apoptosis inhibitor protein 
Nlrp NACHT domain-, leucine rick repeat-, and pyrine domain containing 
protein 
Nod Nucleotide oligomerization domain 
NLR Nod-like receptor 
10 
 
PAMP Pathogen-associated molecular pattern 
PBMC Peripheral blood mononuclear cells 
PCR Polymerase chain reaction 
PI Propidium iodide 
PMN Polymorphonuclear leukocytes 
PRR Pattern-recognition receptor 
RLR Rig-like receptor 
SSc Side scatter 
Th T helper 
Th1 Th type 1 
Th2 Th type 2 
TLR Toll-like receptor 
TNF-α Tumor necrosis factor-α 
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AIMS 
The overall aim with this thesis was to investigate the importance of pattern-recognition 
receptors and neutrophils in cancer inflammation. More specific the aims were to: 
 
 Examine the expression profile and functional importance of toll-like receptors in 
head and neck squamous cell carcinoma. 
 Characterize the expression, function and inflammatory role of nod-like receptors 
in head and neck squamous cell carcinoma. 
 Investigate the phenotype of peripheral leukocytes, and to evaluate the prognostic 
value of the different leukocytes and their markers in head and neck squamous cell 
carcinoma.  
 Characterize different neutrophil subsets and their prognostic role in patients with 
head and neck squamous cell carcinoma. 
 Experimentally compare immune responses induced by allergic rhinitis and head 
and neck squamous cell carcinoma. 
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INTRODUCTION 
HEAD AND NECK SQUAMOUS CELL CARCINOMA 
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer 
worldwide. Despite its origin in the aerodigestive tract it is a heterogeneous group of 
tumors in the oral cavity, oropharynx, hypopharynx, and larynx (Figure 1). Chronic 
inflammation is suggested to constitute a risk factor for the development of cancer. A 
large proportion of HNSCC is induced by tobacco and alcohol consumption, but human 
papillomavirus (HPV) infection has been recognized as an increasingly important risk 
factor for HNSCC, especially for oropharyngeal tumors. The survival of patients with 
HPV positive tumors is better than for patients with HPV negative tumors. Although 
advances in multimodality therapies the overall survival rate has only to a minor degree 
increased the past two decades (1-6). 
 
Figure 1. Schematic overview of the upper airway (http://www.cancer.gov). 
ALLERGIC RHINITIS 
Allergic rhinitis (AR) is a common chronic inflammatory disease induced by an IgE 
mediated reaction to normally harmless antigens called allergens. The reason why some 
people develop AR is unknown, but several theories have been put forward. There seems 
to be a consensus around the idea that AR is the result of the combined influence of 
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genetic and environmental factors, and that respiratory pathogens might play a role. 
Allergy affects millions of people around the world and the prevalence is increasing 
particular in countries with a western life style. AR is characterized by symptoms such as 
sneezing, rhinorrhea, nasal congestion, nasal pruritus, and ocular pruritus/irritation upon 
allergen exposure. It also affects the quality of life, such as work performance, daily 
activity, and sleep (7, 8).  
The existence of an association between allergy and cancer development has been 
debated for several years. The discussion is entirely based on information derived from 
epidemiological studies with diverse outcomes (9-13). Three different perspectives 
currently dominate the discussion; the antigenic stimulation hypothesis, the immune 
surveillance theory, and the prophylaxis postulate. The antigenic stimulation hypothesis 
states that atopic inflammation causes oxidative damage that activates mutations in tumor 
suppressor genes, post-translational modifications in proteins involved in DNA repair, or 
apoptotic control. Altogether, this is said to enhance the development of cancer. The 
immune surveillance theory proposes that atopy is a consequence of a generalized 
enhanced immune responsiveness that can detect and eradicate dysregulated cells. This 
would decrease the risk for the development of cancer. The prophylaxis postulate is based 
on the assumption that patients with allergy tend to avoid environments with increased 
risk for allergen exposure, and such behavior also prevents exposure to microorganisms, 
toxins, and environment contaminants known to promote cancer development (13-15). 
THE IMMUNE SYSTEM 
THE INNATE IMMUNE SYSTEM 
The immune system is traditionally divided into an adaptive and an innate branch. The 
innate part of the system is the first line of defense against pathogens. It is thought to be 
fast and non-specific, and comprises physical and chemical barriers, anti-microbial 
peptides, pattern-recognition receptors (PRRs) as well as different kinds of cells, including 
neutrophils and eosinophils (16, 17).  
PATTERN-RECOGNITION RECEPTORS 
PRRs are an important part of the innate immune system that recognizes conserved 
molecular motifs of microbial origin called pathogen-associated molecular patterns 
(PAMPs). To date, the PRRs consist of at least three receptor families; Toll-like receptors 
(TLRs), Nucleotide oligomerization domain (Nod)-like receptors (NLRs), and Rig-like 
receptors (RLRs). To ensure an effective detection and clearance the different receptor 
families recognize different classes of pathogens. TLRs sense bacteria, viruses, protozoa, 
and fungi, NLRs identify bacteria, and RLRs recognize viruses. In addition, the different 
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receptors are located at various cellular compartments; TLRs are positioned at the cell 
surface and in the endosomes, whereas the NLRs and RLRs are located in the cytosol 
(Figure 2). Despite the protective effect of PRRs against infections evidence suggests a 
role for these receptors in the pathogenesis of various diseases.  
 
Figure 2. Outline of the TLR and NLR family and their cognate ligands. The surface TLRs recognize 
structures from mainly bacteria, whereas the endosomal members sense nucleic acid from primarily 
viruses. The NLRs located in the cytosol identify danger signals and peptidoglycans from bacteria.   
TOLL-LIKE RECEPTORS 
TLRs were the first recognized PRRs, and have since then been extensively examined. 10 
members have been demonstrated in humans both at the cell surface (TLR1, TLR2, 
TLR4, TLR5, TLR6, and TLR10) and intracellulary in the endosomes (TLR3, TLR7, 
TLR8, and TLR9). The TLRs positioned at the cell surface predominantly identify 
bacterial structures, whereas those receptors that are located in the endosomes sense viral 
components. Each TLR recognizes specific PAMPs. TLR2 acts in a heterodimer in 
concert with TLR1 or TLR6 to respond to diacyl (TLR1/2) and triacyl (TLR2/6) 
lipopeptides, lipoteichoic acids, peptidoglycan, and zymosan. TLR3 is involved in the 
recognition of double stranded RNA from viruses, TLR4 senses lipopolysaccharide 
(LPS), TLR5 identifies the bacterial component flagellin, TLR7 and TLR8 mediate 
responses to single stranded viral RNA, and TLR9 has been demonstrated to sense 
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bacterial and viral DNA containing unmethylated CpG motifs. No specific ligand has so 
far been identified for TLR10 (18-21).  
TLRs have been demonstrated in various cells and tissues including epithelial cells, 
neutrophils, dendritic cells, lymphocytes, nasal mucosa, and tonsils (22-25). Tumor cells 
have also been shown to express TLRs, often with levels that differ from what is seen in 
normal tissues (26, 27). The importance of TLRs in host responses to tumors became 
evident as polymorphism in TLR genes was found to be associated with susceptibility to 
cancer (28-31). Increasing evidence suggests that TLRs might play a dual role in cancer 
progression. TLR3 has been demonstrated to directly inhibit tumor growth by inducing 
apoptosis and to decrease proliferation in human breast, melanoma, and prostate cancer 
cells (32-34), whereas TLR4 seems to promote tumor growth in human ovarian cancers 
and HNSCC (26, 35). It also appears as the same TLRs can induce both anti-tumorigenic 
and pro-tumorigenic effects all depending of the types of tumors and tissues involved. 
For instance, TLR9 has been demonstrated to induce cell proliferation and to increase 
invasiveness in breast cancer cells (36), whereas it inhibits proliferation and causes cell 
death in neuroblastoma cells (37) 
The TLR7/8 agonist Imiquidmod is used clinically for treating basal cell carcinoma. 
Today there are many TLR ligands in clinical trials both as adjuvants in cancer 
immunotherapies and as monotherapy. In particular, TLR7/8 and TLR9 agonists have 
attracted attention due to their leukocyte mediated and tumor induced anti-tumor 
functions (38).  
NOD-LIKE RECEPTORS 
The NLR family consists of more than 20 known members in humans. Based on the 
nature of the N-terminal, the NLRs can be divided into three subfamilies; caspase 
recruitment domain (CARD)-containing NODs, NACHT-, leucine rich repeat-, and 
pyrine domain containing proteins (Nlrps), and baculovirus inhibitor repeat containing 
neuronal apoptosis inhibitor proteins (Naips) (39-41). The NLRs are expressed by a 
variety of cells of both the innate and the adaptive systems. Presence of Nod1 and Nod2 
has for instance been demonstrated in airway epithelial cells, lymphocytes, and 
neutrophils (42-46). The NLRs are located in the cell cytosol where they respond to 
bacterial proteins and danger signals. So far, specific ligands have been identified for 
Nod1, Nod2, and Nlrp3. Nod1 and Nod2 recognize the major component of the 
bacterial cell wall, peptidoglycan. More specifically, Nod1 detects γ-D-glutamyl-meso-
diaminopimelic acid (iE-DAP), specific for Gram-negative bacteria, and Nod2 senses 
muramyldipeptide, a component of all types of bacterial peptidoglycans (39-41). In 
contrast, Nlrp3 recognizes microbial products and danger signals released by injured 
or/and dying cells. It has also been shown to respond to aluminium adjuvants used in 
many vaccines (47, 48).  
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NLRs have been associated with cancer, but their role in tumor development is still far 
from understood. Most data indicate that NLRs might have a protective role. For 
instance, Nod1 has been demonstrated to have a suppressive effect against colon cancer 
and estrogen sensitive breast cancer (49, 50), and Nlrp3 has shown protective effects 
against the development of colon cancer (51, 52). Conversely, genetic variations in Nod2 
have been associated with cancer in some studies, but not linked to cancers in others (53-
56).   
NEUTROPHILS 
Neutrophils are essential for the innate immune response. They have a key role in 
eliminating invading pathogens and in promoting tissue repair. Their half-life in blood is 
normally about 6 to 8 h, but it can be significantly extended upon migration into inflamed 
tissue (57). Neutrophils respond quickly to intruding pathogens by migrating into 
inflamed tissue where they phagocytose and kill bacteria. This is followed by rapid 
apoptosis and clearance by resident macrophages (Figure 3). Lately, neutrophils have been 
demonstrated to have functions beyond their role in the acute inflammation. They are for 
instance able to migrate to and reside in lymph nodes as well as to migrate back to the 
peripheral blood (57, 58).   
 
Figure 3. Schematic overview of the recruitment of neutrophils into inflamed tissue. CXCR 1/2 – CXC 
chemokine receptor 1/2; ICAM-1 – Intercellular adhesion molecule-1; IL-8 – Interleukin-8; LFA-1 – 
Leukocyte function associated antigen-1; Mac-1 – Macrophage-1 antigen; PECAM – Platelet endothelial 
cell adhesion molecule; PSGL-1 – P-selectin glycoprotein ligand-1.  
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Neutrophils are thought to be involved in the pathophysiology of cancer and tumor 
progression (59). It has been demonstrated that high levels of tumor-infiltrating 
neutrophils and blood neutrophils are associated with poor clinical outcome (60-62). 
Nonetheless, neutrophils have been attributed both pro- and anti-tumor functions. The 
best characterized pro-tumorigenic effect of neutrophils is related to the inducement and 
regulation of angiogenesis (58, 59, 63, 64). Neutrophils are also able to directly modulate 
the biology of tumor cells by secretion of pro-inflammatory factors that promote motility 
and migration. In addition, neutrophils have been attributed the capacity to promote 
tumor cell invasion and immune suppression by inhibiting anti-tumor effector cells (58, 
59, 63, 65). Despite the evidence for a tumor promoting role of neutrophils there are also 
convincing results that support an anti-tumorigenic activity of these cells. The release of 
antimicrobial and cytotoxic granule contents by neutrophils has the potential to eliminate 
malignant cells, and the secretion of cytokines and chemokines may activate other anti-
tumor effector cells (58, 59, 64). 
The pro- and anti-tumor functions of neutrophils illustrate the plasticity and dichotomy 
of this cell type. Until recently, neutrophils were thought to consist of one population, but 
accumulating evidence proposes that there are distinct neutrophil subsets with diverse 
roles in infection, inflammation and cancer (66-68). Pillay et al recently identified three 
distinct neutrophil subsets in humans based on the expression of CD16 and CD62L. The 
CD16dim CD62Lhigh subset showed a banded nuclear morphology characteristic of 
neutrophils derived from the bone marrow, the CD16high CD62Lhigh cells had the 
phenotype of normal mature neutrophils, and the CD16high CD62Ldim population 
demonstrated a hypersegmented nucleus (67). 
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MATERIALS AND METHODS 
STUDY POPULATIONS 
Fresh human materials were used in all studies. The studies were approved by the ethics 
committee at Lund University and/or Karolinska Institutet and an informed consent was 
obtained from all participants. 
- In PAPER I, three HNSCC biopsies were collected and primary human nasal 
epithelial cells (HNEC) were obtained from six healthy control patients.  
- In PAPER II, six nasal biopsies from healthy controls and four HNSCC biopsies 
were used. In addition, HNEC were isolated from seven healthy donors.  
- In PAPER III, blood was acquired from 20 newly diagnosed still untreated HNSCC 
patients and from 20 healthy controls.  
- In PAPER IV, blood from 31 newly diagnosed still untreated HNSCC patients and 
19 healthy controls was obtained.  
- In PAPER V, blood was obtained from ten newly diagnosed still untreated patients 
with HNSCC, 13 patients with AR sampled during pollen season, and 10 healthy 
controls.  
METHODS 
The studies were performed at Skåne University Hospital Malmö (PAPERS I-V), 
Karolinska Institutet, and Karolinska University Hospital (PAPERS IV-V).  
CELL CULTURE 
In PAPERS I-II, primary HNEC were isolated from healthy non-smoking individuals by 
nasal brushing of the inferior turbinates of both nostrils. After brushing, the cell mixture 
was centrifuged and grown on collagen coated tissue culture flasks. The cells were 
cultured in airway epithelial cell growth medium supplemented with 0.4 % bovine 
pituitary extract, 10 ng/ml epidermal growth factor, 5 µg/ml insulin, 0.5 µg/ml 
hydrocortisone, 0.5 µg/ml epinephrine, 6.7 ng/ml triiodothyronine, 10 µg/ml transferrin, 
0.1 ng/ml retinoic acid, 100 U/ml pencillin, and 100 µg/ml streptomycin. Primary 
epithelial cells in passage 1-4 were used in the experiments.  
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The human pharyngeal carcinoma cell lines Detroit-562 (PAPERS I-II) and FaDu (PAPER II) 
from ATCC were used as a model for HNSCC. These cells were cultured in minimum 
essential medium (MEM) with Earl’s salt and 2 mM L-glutamine, and supplemented with 
FBS. The complete medium for Detroit-562 also contained 1 mM sodium pyruvate, 0.1 
mM non-essential amino acids, 50 µg/ml gentamicin, and 0.25 µg/ml fungizone, whereas 
only 100 U/ml pencillin and 100 µg/ml streptomycin were added to the medium for 
FaDu. 
The non-tumorigenic cell line NL-20 (ATCC) derived from a normal bronchus was used 
as control cells to the HNSCC cell lines. The cells were cultured in Ham’s F12 medium 
supplemented with 2.7 g/l glucose, 5 µg/ml insulin, 10 ng/ml epidermal growth factor, 1 
µg/ml transferrin, 500 ng/ml hydrocortisone, 2mM L-glutamine, 0.1 mM non-essential 
amino acids, 50 µg/ml gentamicin, and 4% FBS. 
All cells were cultured at 37°C in humidified 5 % CO2. Before each experiments, 
epithelial cells were plated on 24-well culture plates at a concentration of 250 000 cells/ml 
and incubated over night.   
CELL ISOLATION 
Ficoll-PaqueTM was used to separate polymorphonuclear leukocytes (PMN) and peripheral 
blood mononuclear cells (PBMC) in blood. PMN and erythrocytes with high density 
sedimented to the bottom of the tube, and PBMC with low density could be found at the 
interface of plasma (above) and Ficoll-PaqueTM (below). To recover pure PMN the 
erythrocytes have to be lysed. This was done with ammonium chloride buffer. The cells 
were then cultured in RPMI-1640 supplemented with 0.3 g/l L-glutamine, 100 U/ml 
penicillin, 100 µg/ml streptomycin, and 10 % autologous plasma to a concentration of 1 
× 106 PBMC and 4 × 106 PMN at 37°C in humidified 5 % CO2 . 
PMN was isolated from 11 HNSCC patients (PAPERS IV), whereas both PMN and PBMC 
were recovered from 13 patients with AR, ten HNSCC patients, and ten healthy controls 
(PAPER V).   
IMMUNOHISTOCHEMISTRY 
Immunohistochemistry is an antibody-based method to identify proteins in tissues and 
cells. The antibody-protein conjugation is detected with an enzyme-labeled polymer 
conjugated secondary antibody. In our studies, horseradish peroxidase (HRP) was used as 
enzyme. After incubation with a substrate, a positive immunoreactivity occurs. If DAB is 
used as a substrate, a brown color can be seen. To provide contrast to the sections and to 
visualize the nuclei, the slides are usually counterstained with haematoxylin. To rule out 
unspecific background staining, negative controls for mouse and/or rabbit primary 
antibodies are used.  
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Immunohistochemistry was used in PAPERS I-II to detect the expression of TLRs and 
NLRs in the epithelium of nasal biopsies and in HNSCC biopsies.     
REAL-TIME RT-PCR 
Real-time PCR is used to quantitate the gene expression based on mRNA manifestation 
in cells and tissues. Before real-time PCR can be performed, the total RNA has to be 
extracted from the cells of interest followed by reverse transcriptase of RNA into cDNA. 
The obtained cDNA can be used for real-time PCR where a cyclic heating and cooling 
procedure denatures the double-stranded cDNA, enables attachment of sequence specific 
oligonucleotide primers or probes, and promotes extension of new DNA strands. This 
then starts over for another set of cycles. Real-time PCR can be performed with either 
sequence specific primers or probes. Primers are used in the presence of fluorescent dyes 
such as SYBR® green, which emits a fluorescent signal when binding to double stranded 
DNA. Probes, on the other hand, are labeled with a reporter fluorophore and a quencher 
fluorophore, and during DNA amplification these two fluorophores are separated, which 
enables the reporter fluorophore to emit a fluorescent signal. When the level of 
fluorescence reaches a predetermined value a cycle threshold (CT) value can be 
determined. The relative amount of mRNA is determined by subtracting the CT value of 
the investigated gene with the CT value of the housekeeping gene, and expressed in 
relation to 100 000 mRNA molecules of the housekeeping gene (100 000 × 2-ΔCT) (69). β-
actin was used as housekeeping gene.  
In this thesis, RNA was extracted from isolated cells with RNeasy mini kit from Qiagen, 
and the RNA quality and concentration was determined by spectrophotometry based on 
the wavelength absorption ratio (260/280 nm), all samples in the range 1.7-2.1. 
Subsequently, RNA was reversely transcribed into cDNA using Omniscript reverse 
transcriptase kit (Qiagen) with oligo-dT primer.  
Real-time PCR was performed either on a Smart cycler II (Cepheid; PAPERS I) or a 
Stratagene Mx300 (Aglient Technologies; PAPER II). To detect TLR probes (PAPER I) 
TaqMan Universal PCR brilliant II QPCR Master Mix, No AmpErase UNG and assay-
on-Demand gene expression products (Applied Biosystems) were used, whereas 
Stratagene Brilliant® QPCR Mastermix (Aglient Technologies) was utilized to detect 
NLR probes in PAPER II.  
FLOW CYTOMETRY 
Flow cytometry is a method that analyzes the physical and chemical properties of 
individual cells based on how they scatter light from a laser beam. Through different 
detectors flow cytometry gives information about cell size (displayed by forward scatter; 
FSc), granularity (displayed by side scatter; SSc), and fluorescence intensity of 
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fluorochrome conjugated antibodies against extra- or intracellular antigens to provide 
information about cell phenotype. By gating on FSc and SSc lymphocytes, monocytes, 
and granulocytes can be distinguished (Figure 4). Analyzes were made on a Coulter Epics 
XL, FC500, Navios (Beckman Coulter), or a BD LSRFortessa (BD Bioscience). Data 
were analyzed with Expo32 ADC software, CXP analysis software (Applied cytometry 
software), or FlowJo software (Tree Star Inc.).  
 
Figure 4. Flow cytometry identifications of lymphocytes, monocytes, and granulocytes in peripheral 
blood based on FSc and SSc properties. By further plotting CD16 versus FSc from granulocytes 
neutrophils can be distinguished. 
In PAPERS I-II, flow cytometry was used to determine the expression of TLRs and NLRs 
in epithelial cells, and to identify the effects of TLR and NLR agonists on the expression 
of the epithelial cell activation marker intercellular adhesion molecule (ICAM)-1. In 
addition, the stimulatory effects on viability and apoptosis were established with Annexin 
V (ANXV) and propidium iodide (PI). ANXV binds to phosphatidylserine that is 
translocated to the plasma membrane during apoptosis, whereas PI is a nucleic acid 
binding dye used to discriminate between apoptotic and dead cells (70). The leukocyte 
phenotypes were assessed in patients with HNSCC and healthy controls with flow 
cytometry (PAPER III). In PAPERS IV-V, neutrophil subsets were characterized based on the 
expression of CD16 and CD62L, neutrophils were identified as CD16+ granulocytes and 
Th cells as CD4+ lymphocytes. Flow cytometry was also used to characterize the 
neutrophil and the Th cell responses to TLR agonists by measuring the activation markers 
CD11b, CD25, CD69, and CD98.   
ELISA 
ELISA is a specific method for quantification of antigens and/or antibodies in for 
instance cell culture supernatants. The ELISAs used were of sandwich type where a 
microplate is pre-coated with antibodies against the antigen of interest. When standards 
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(with known concentration) or samples are added, the antigen binds to the immobilized 
antibody. For detection of antigens, levels of antigen specific enzyme-linked polyclonal 
antibodies are added. As a substrate solution is added the enzyme will be converted into a 
detectable color that is proportional to the amount of antigen. By measuring the color 
intensity with a microplate reader and comparing it to the standards the levels of antigen 
in the sample can be determined.  
In PAPERS I-II, commercial ELISA kits from R&D systems were used to determine the 
concentration of interleukin (IL)-1β, IL-6, IL-8, granulocyte-colony stimulating factor (G-
CSF), and granulocyte monocyte-colony stimulating factor (GM-CSF) in epithelial cell 
culture supernatants. In PAPER IV, PMN cell culture supernatants were assessed for levels 
of IL-8 and IL-6 with ELISA plates from eBisoscience.  
LUMINEX MULTIPLEX IMMUNOASSAY 
Luminex multiplex immunoassay is a method that quantifies multiplex proteins or 
peptides at the same time in one sample of for instance serum or cell culture supernatants. 
The assay principle is similar to that of a sandwich ELISA, but with the exception that the 
antibodies directed against the antigen of interest are covalently coupled to magnetic 
beads dyed with fluorescent dyes. The fluorescently dyed beads each have a distinct color 
code that permits discrimination of individual antigens. When the standards (with known 
concentration) or samples are assessed, the antigen binds to the antibody-bead complex. 
For detection, the biotinylated detection antibody is added followed by addition of 
streptavidin-phycoerythrin conjugate. Phycoerythrin serves as a fluorescent 
indicator/reporter. The median fluorescent intensity is then measured with for instance 
the Bio-Plex system from Bio-Rad Laboratories, and the level of antigens in the samples 
is determined by comparison to the standards.   
In PAPER V, the cytokine profile in serum and supernatants from TLR stimulated PBMC 
from patients with AR, HNSCC patients, and healthy individuals were detected with the 
Bio-Plex Pro Human Cytokine 17-plex assay from Bio-Rad Laboratories. 
STATISTICAL ANALYSES 
Statistical analysis was performed using GraphPad Prism 5. In PAPERS I-II AND IV-V, data 
were presented as mean ± standard error of the mean (SEM), whereas individual values 
and a horizontal line representing the mean were displayed in PAPERS III-IV. A p-value ≤ 
0.05 was considered statistically significant, and n is equal to the number of independent 
donors or experiments performed.   
Distribution of data was assessed using D’Agostino and Pearson omnibus normality test. 
Normally distributed data were analyzed with parametric tests, whereas non-parametric 
tests were used to analyze not normally distributed data.  
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When two sets of normally distributed paired data were compared paired t-tests were 
used, and for comparison of more than two sets of normally distributed paired data with a 
control one-way repeated measures analysis of variance (ANOVA) with Dunett’s post-
test was utilized. For two sets of normally distributed unpaired data, student’s t-test with 
Welch correction if the variance was non-homogenous was used. ANOVA with Tukey’s 
post test was used to analyze more than two sets of normally distributed paired data with 
each other. The survival function from life-time data was estimated using Kaplan-Meier 
analysis, and a log rank test was utilized to examine the significance of the different 
survival distribution between the two groups. The nonparametric Mann-Whitney test was 
used to determine the statistical difference between different groups, and for paired data 
the nonparametric Wilcoxon signed rank test was utilized.  
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RESULTS AND COMMENTS 
TOLL-LIKE AND NOD-LIKE RECEPTORS IN HEAD AND NECK SQUAMOUS 
CELL CARCINOMA (PAPERS I-II) 
RESULTS 
TLRs have previously been demonstrated to have anti-tumorigenic properties, and Nod1 
has been attributed a protective role against colon cancer and estrogen-sensitive tumors 
(32, 49, 50, 71). However, the role of TLRs and NLRs in HNSCC is far from understood. 
The present studies were designed to characterize the TLR and NLR expression and 
function in HNSCC. To this end, the HNSCC cell lines Detroit-562 and FaDu were used 
as a model of HNSCC. In PAPER I, Detroit-562 was compared to the healthy bronchial 
cell line NL-20 and primary HNEC. In PAPER II, Detroit-562 and FaDu were compared 
to HNEC. 
High mRNA levels of TLR2, TLR3, and TLR5 were seen in Detroit-562. HNEC showed 
varied expression levels of TLR1-5, whereas low mRNA levels of TLR3 and TLR4 were 
present in NL-20. The expression of TLR2, TLR3, and TLR5 in Detroit-562 was 
confirmed with flow cytometric protein analyzes. NL-20 showed presence of both TLR2 
and TLR3 proteins. Nod1 and Naip were consistently expressed in the two cancer cell 
lines as demonstrated by both mRNA and protein studies. HNEC showed a broader 
NLR profile with presence of all NLRs investigated, i.e. Nod1, Nod2, Nlrp1, Nlrp3, and 
Naip at both mRNA and protein level (Figure 5).  
The expression of TLR2, TLR3, TLR5, Nod1, and Naip was corroborated in HNSCC 
biopsies with immunohistochemistry. These biopsies also showed an inconsistent 
expression of Nod2 and Nlrp3 (Figure 6). 
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Figure 5. The TLR and NLR expression profiles in Detroit-562, FaDu, NL-20, and HNEC. The mRNA 
expression of TLR1-6, Nod1, Nod2, Nlrp1, Nlrp3, and Naip was investigated with real-time RT-PCR. 
Values are depicted in relation to the housekeeping gene β-actin 100 000 × 2-ΔCT, and presented as mean ± 
SEM. This was followed by protein analyses with flow cytometry. Open histogram represent antibodies 
against TLR2, TLR3, TLR5, Nod1, Nod2, Nlrp1, Nlrp3, and Naip, light grey is denoting the isotype 
control, and dark gray a secondary antibody used as an additional control for Nod1 and Naip. * p≤0.05; 
** p≤0.01.   
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Figure 6. TLR and NLR expression in HNSCC biopsies. The protein expression of TLR2, TLR3, TLR5, 
Nod1, Nod2, Nlrp1, Nlrp3, and Naip was confirmed in HNSCC biopsies with immunohistochemistry. 
The NLR stained and control (ctr) sections were counterstained with haematoxylin (magnification 200X).  
Specific NLR ligands exist for Nod1, Nod2, and Nlrp3, but since only Nod1 was found 
to be consistently expressed by the HNSCC cell lines the functional part of the NLR 
studies was focused on Nod1. Since TLR2, TLR3, and TLR5 were expressed by Detroit-
562, their function was also examined. To this end, the cells were incubated with or 
without their cognate ligands Pam3CSK4, poly(I:C), flagellin, and iE-DAP. Tumor 
necrosis factor (TNF)-α was used as positive control. All ligands activated the HNSCC 
cell lines. They up-regulated the expression of ICAM-1 (Figure 7), and gave rise to 
specific cytokine profiles. Pam3CSK4, poly(I:C), and flagellin increased the secretion of 
IL-6 and IL-8. Poly(I:C) also induced the release of IL-1β. Nod1 activation generated an 
increased production of G-CSF and GM-CSF (Figure 8).  
 
Figure 7. TLR2, 3, 5, and Nod1 stimulation induced the expression of ICAM-1 in the HNSCC cell lines. 
Detroit-562 was incubated with the TLR2, 3, 5, and Nod1 agonists, Pam3CSK4, poly(I:C), flagellin, and 
iE-DAP, respectively, and FaDu with iE-DAP for 24 h. The effects on ICAM-1 expression were 
examined with flow cytometry. MFI=mean fluorescence intensity; * p≤0.05; ** p≤0.01; *** p≤0.001.  
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Figure 8. TLR2, 3, 5, and Nod1 stimulation induced specific cytokine secretion profiles in HNSCC. 
Detroit-562 was stimulated with Pam3CSK4, poly(I:C), and flagellin for 24 h, and Detroit-562 and FaDu 
were stimulated with iE-DAP for 24h. The cell culture free supernatants were then analyzed for the 
secretion of IL-8, IL-6, IL-1β, G-CSF, and GM-CSF with ELISA. * p≤0.05; ** p≤0.01; *** p≤0.001.   
Poly(I:C) induced the strongest response with an enhancement of IL-1β, IL-6, and IL-8 
secretion in HNEC, and IL-6 and IL-8 in NL-20 (Figure 9). The secretion of IL-6 was 
also increased in HNEC after stimulation with flagellin. No effects were observed after 
iE-DAP stimulation in the healthy cells.  
TLR2, TLR3, and TLR5 activation decreased the viability of Detroit-562 cells, and 
accordingly a high amount of apoptotic and dead cells was seen. Corresponding effects 
were not seen in the healthy cells (Figure 10).  
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Figure 9. TLR induced cytokine secretion in healthy control cells. NL-20 and HNEC were incubated 
with Pam3CSK4, poly(I:C), and flagellin for 24 h, and the cell culture supernatants were analyzed for levels 
of IL-8, IL-6, and IL-1β. * p≤0.05; ** p≤0.01. 
 
Figure 10. Decreased viability in Detroit-562 after TLR activation. Detroit-562 was incubated with 
Pam3CSK4, poly(I:C), and flagellin for 24 h, and analyzed for the percentage of viable (ANXV-PI-), 
apoptotic (ANXV-PI+), and dead cells (ANXV+PI+) with flow cytometry. * p≤0.05; ** p≤0.01. 
COMMENTS 
The present studies demonstrated the presence of TLR2, TLR3, TLR5, Nod1, and Naip 
in HNSCC. Ligand stimulation of TLR2, TLR3, TLR5, and Nod1 activated the HNSCC 
cells in a way that differed from what was seen in healthy cells. In addition, TLRs and 
Nod1 stimulation exhibited separate activation patterns. 
The response to Nod1 activation in HNSCC cells was relatively modest, whereas the 
reaction to a corresponding TLR stimulation was more marked. Hence, the biological 
significance of the former stimulation could be questioned. However, even though the 
response of Nod1 to iE-DAP stimulation in HNSCC in terms of ICAM-1 expression and 
GM-CSF production was somewhat limited it was consistent in two different squamous 
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cell carcinoma cell lines, Detroit-562 and FaDu. This consistency strengthens the idea of 
Nod1 as an enhancer of the inflammatory response in tumorigenic cells. 
The present studies further highlight the importance of TLR and NLR activation in 
cancer. TLR stimulation in HNSCC induced a robust inflammatory response in 
combination with a decreased survival of the tumor cells, thus showing anti-tumorigenic 
properties. NLR stimulation, on the other hand, induced a more pro-tumorigenic kind of 
inflammation. Different PRRs have been shown to induce anti-tumorigenic effects or 
pro-tumorigenic responses in the same tumor type (38, 72). TLR2, TLR3, and TLR5 
appear to have mainly anti-tumorigenic properties in HNSCC, whereas TLR4 seems to 
promote the development of HNSCC (26). In addition, the same PRR receptor can 
exhibit different characteristics depending on the tumor type. For instance, we showed 
that Nod1 induces an inflammation that seems to have pro-tumorigenic effects, whereas 
Chen et al and da Silva Correia et al reported that Nod1 displays a protective role against 
development of colon cancer and estrogen-sensitive tumors (49, 50).  
The immune system is important in the defense against tumors, but it may also have pro-
tumorigenic properties. Depending on the activation and induction of the immune cells 
they will attain an anti- or pro-tumorigenic profile (73, 74). In the present investigation 
TLR induced a pro-inflammatory response in HNSCC with a potential to mobilize 
leukocytes, especially neutrophils, by the induction of IL-8. In PAPERS III-IV, we 
demonstrated that increased activation of neutrophils predicts better prognosis, and that 
an increased infiltration of CD16high CD62Ldim neutrophils might account for this. 
Therefore, the TLR induced inflammation seen might be anti-tumorigenic in nature. IL-8 
has been demonstrated to promote angiogenesis, which is important for the development 
of cancer (75, 76). In this case angiogenesis would further increase the amount of 
infiltrating neutrophils, especially the CD16high CD62Ldim cells, supporting the theory of a 
TLR induced anti-tumorigenic response.   
In contrast to the TLRs, Nod1 induced an inflammation characterized by an increase in 
G-CSF and GM-CSF, which are hematopoetic growth factors with angiogenic functions. 
The ability of these mediators to attract, and stimulate proliferation and maturation of 
granulocytes and macrophages are often used to ameliorate cancer therapy side effects 
(77, 78). However, GM-CSF has also been demonstrated to trigger the mobilization of 
immune suppressive CD34+ cells that have the ability to impair the anti-tumor immune 
response. GM-CSF and G-CSF have also been associated with a poor HNSCC prognosis 
and with an ability to promote proliferation and migration of tumor cells (79-81). Hence, 
the Nod1 induced inflammation might be regarded as anti-tumorigenic.  
This part of the result section demonstrates that HNSCC have altered their TLR and 
NLR expression and their functional responses to the corresponding ligands. This gives 
an impression that the HNSCC cells have exploited TLRs and NLRs with a somewhat 
contradictory outcome.  
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NEUTROPHIL INFLAMMATION IN HEAD AND NECK SQUAMOUS CELL 
CARCINOMA (PAPERS III-IV) 
RESULTS 
HNSCC is known to cause immune suppression, but how the immune system is affected 
is not fully established. Patients with HNSCC have an altered neutrophil activation (82, 
83), and accumulating evidence has indicated the existence of distinct neutrophil subsets 
with specific roles in cancer inflammation (67, 84). The presented investigations were 
designed to characterize different neutrophil subsets, and to evaluate their prognostic role 
in HNSCC. 
HNSCC patients were found to have higher levels of leukocytes and neutrophils in blood 
than healthy controls. Consequently, the neutrophil/lymphocyte ratio was higher in the 
cancer patients compared to the control individuals, and a high ratio predicted worse 
prognosis (Figure 11).  
 
Figure 11. The number of total leukocytes, neutrophils, and the neutrophil/lymfocyte ratio in blood from 
HNSCC patients and healthy control individuals was determined with leukocyte differential count analysis. 
A Kaplan-Meier survival analysis following diagnosis of HNSCC patients, before start of treatment, was 
also performed. * p≤0.05; ** p≤0.01; *** p≤0.001. 
 
Leukocytes
C
on
tro
ls
H
N
SC
C
0
5
10
15
20 ***
C
e
ll
 n
u
m
b
e
r 
(x
1
0
9
/l
)
Neutrophils
C
on
tro
ls
H
N
SC
C
0
5
10
15
20
**
C
e
ll
 n
u
m
b
e
r 
(x
1
0
9
/l
)
Neutrophil/Lymphocyte ratio
C
on
tro
ls
H
N
SC
C
0
5
10
15
20
25 *
N
e
u
tr
o
p
h
il
 c
o
u
n
t 
/
L
y
m
p
h
o
c
y
te
 c
o
u
n
t
Neutrophil/Lymphocyte ratio
0 5 10 15 20
0
20
40
60
80
100
High
Low
* p=0.0312
Time (months)
P
e
rc
e
n
t 
s
u
rv
iv
a
l
34 
 
Three different neutrophil subsets; CD16dim CD62Lhigh, CD16high CD62Lhigh, and 
CD16high CD62Ldim, were found in the circulation of these patients. In comparison to the 
healthy controls, the HNSCC patients had a higher percentage of CD16high CD62Ldim 
cells. The patients could be divided into two distinct groups; those with a high level and 
those with a more “normal” percentage of CD16high CD62Ldim cells. The patients with a 
high percentage of CD16high CD62Ldim neutrophils had a better prognosis than the 
patients with a more “normal” amount (Figure 12).  
 
Figure 12. Increased CD16high CD62Ldim neutrophils predict better prognosis in patients with HNSCC. 
The neutrophil subsets; CD16dim CD62Lhigh, CD16high CD62Lhigh, and CD16high CD62Ldim cells, were 
identified with flow cytometry in blood from HNSCC patients and controls. A Kaplan-Meier survival 
analysis following diagnosis of HNSCC patients, before start of treatment, was also performed. * p≤0.05; 
** p≤0.01.  
It is also worth noticing that CD16high CD62Ldim neutrophils had a higher CD11b and 
CD18 expression, and a decreased IL-8 level as compared to the CD16dim CD62Lhigh and 
CD16high CD62Lhigh cells (Figure 13).  
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Figure 13. CD16high CD62Ldim neutrophils displayed an active phenotype. The three different neutrophil 
subsets were characterized with flow cytometry upon the expression of CD11b, CD18, and IL-8 in blood 
obtained from HNSCC patients. * p≤0.05; ** p≤0.01; *** p≤0.001. 
COMMENTS 
The second part of this thesis focuses on the three different neutrophil subsets that were 
recently identified by Pillay et al (67). The increased number of leukocytes, neutrophils, 
and the high neutrophil/lymphocyte ratio indicate that there is an ongoing inflammation 
in patients with HNSCC. The neutrophil/lymphocyte ratio has been suggested to reflect 
an ongoing systemic inflammation (85). The increased inflammatory activity among the 
cancer patients seems to be related to an increase in neutrophil activation. However, it is 
widely debated whether the neutrophil inflammation is beneficial or of disadvantage for 
the patient. Regardless, inflammation is considered to be an important factor in the 
defense against tumors. T cells and the adaptive branch of the immune system have the 
ability to identify and destroy malignantly transformed cells. 
The neutrophil/lymphocyte ratio has been suggested to be a prognostic factor for various 
cancers. The ratio per se reflects an elevated number of neutrophils, and consequently an 
increase in neutrophils seems to be related to a poor prognosis (86-89). Generally the 
elevated neutrophil numbers is thought to reflect an increase in the amount of immature 
neutrophils (90). This may not be true for HNSCC. In the present study, an elevated 
percentage of activated neutrophils, CD16high CD62Ldim cells, were detected in the cancer 
patients and correlated to a better prognosis. Pillay et al suggested that the CD16high 
CD62Ldim subset causes immunosuppression by suppressing T cell proliferation (67). 
There are clinical studies demonstrating that high numbers of tumor infiltrating and blood 
neutrophils is associated with poor prognosis (60, 61). At the same time, there is evidence 
that neutrophils have anti-tumorigenic properties (91-93). It has been proposed that 
activated neutrophils can elicit anti-tumorigenic activity. This agrees with our studies 
showing that activated CD16high CD62Ldim neutrophils, demonstrated by a decreased 
CD62L expression, a reduced IL-8 level, and an increased Mac-1 complex, were 
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associated with an increased survival of HNSCC patients. In addition, the Mac-1 
complex, i.e. CD11b and CD18, has previously been demonstrated to be of importance 
for the tumor cytolytic function of neutrophils (92). 
Altogether, this emphasizes the importance of neutrophils and neutrophil inflammation in 
patients with HNSCC. Activated neutrophils seem to be beneficial for the survival, 
perhaps as a reflection of their anti-tumorigenic properties. This also signifies the tight 
link between the immune phenotype, the anti-tumorigenic immune response, and the 
survival of the patients.  
IMMUNE REACTIONS IN ALLERGIC RHINITIS VERSUS HEAD AND NECK 
SQUAMOUS CELL CARCINOMA (PAPER V)  
RESULTS 
The information about immunologic differences between allergy and cancer is scarce. 
Several epidemiological studies have investigated the relation between these two diseases 
with contradicting results. The present study was designed to investigate and compare 
immune responses induced by AR and HNSCC.  
Sera from patients with HNSCC exhibited a slight increase, although not significant, of 
innate related cytokines like IL-1β, IL-17, monocyte chemotactic protein (MCP)-1, and 
macrophage inflammatory protein (MIP)-1β as compared to sera from AR patients and 
healthy controls. In addition, IL-7 was increased in sera from HNSCC patients compared 
to sera from healthy individuals. As expected, sera from allergic patients displayed 
elevated levels of Th2 cytokines like IL-5 and IL-13 compared to cancer patients and 
controls. Sera from AR patients also showed lower levels of IL-1β compared to healthy 
controls. Increased levels of the T cell related cytokine IL-7 as well as a tendency towards 
an elevated amount of Th1 cytokines like IL-12 and IFN-γ were also seen among the 
allergic patients (Figure 14).  
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Figure 14. Cytokine profiles in sera from HNSCC patients, AR patients, and controls. Sera was obtained 
from patients with HNSCC, AR, and healthy controls, and analyzed with Luminex Multiplex 
Immunoassay for cytokine levels. * p≤0.05. 
Isolated PMN from AR, HNSCC, and healthy control patients were stimulated with or 
without the TLR2, TLR4, TLR7, and TLR9 ligands, Pam3CSK4, LPS, R837, and CpG, 
respectively. PMN from HNSCC patients displayed a higher basal secretion of IL-8 and 
generally responded stronger to TLR stimulation, demonstrated by an enhanced 
expression of CD11b and CD69, than PMN from both allergic patients and controls 
(Figure 15). 
 
Figure 15. Increased PMN activation in patients with HNSCC. PMN were isolated from blood obtained 
from patients with HNSCC, AR, and controls, and stimulated with or without Pam3CSK4 (1 µg/ml), LPS 
(1 µg/ml), R837 (5 µg/ml), or CpG (0.3 µM) for 4 and 24 h. The cell culture supernatants were analyzed 
for the release of IL-8 with ELISA, whereas the cells were investigated for the expression of CD11b and 
CD69 with flow cytometry. MFI=mean fluorescence intensity; * p≤0.05; ** p≤0.01; *** p≤0.001. 
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When PBMC were stimulated with the same ligands as PMN, PBMC from HNSCC 
patients demonstrated a lower T cell activation than PBMC from AR patients and 
controls. This was seen as a diminished expression of CD25 and CD98 in combination 
with a reduced secretion of cytokines like IL-4, IL-7, and IL-12. In contrast, PBMC from 
allergic patients showed a high secretion of the same T cells related cytokines. A tendency 
towards an increased basal secretion of these cytokines was also revealed among the 
rhinitis patients (Figure 16).  
 
Figure 16. Decreased PBMC activation in HNSCC patients. PBMC were isolated from blood collected 
from patients with HNSCC, AR, and healthy individuals, and cultured with Pam3CSK4 (1 µg/ml), LPS (1 
µg/ml), R837 (5 µg/ml), or CpG (0.3 µM) for 24 and 72 h. The Th cells were examined for the expression 
of CD25 and CD98 with flow cytometry, and the secreted cytokine profile was investigated in cell culture 
supernatants with Luminex Multiplex Immunoassay. MFI=mean fluorescence intensity; * p≤0.05; ** 
p≤0.01; *** p≤0.001. 
HNSCC biopsies and nasal biopsies from healthy individuals and AR patients, outside 
and during pollen season, were collected and investigated for the expression of Nod2 
mRNA. Cancer biopsies showed a higher Nod2 mRNA expression than nasal biopsies 
from controls, and allergic patients both outside and during pollen season. No differences 
were found between AR patients and healthy controls (Figure 17).   
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Figure 17. High Nod2 expression in HNSCC biopsies. Nod2 mRNA expression in HNSCC biopsies and 
nasal biopsies from healthy controls and AR patients outside and during pollen season. The Nod2 mRNA 
expression was investigated with real-time RT-PCR. Values are depicted in relation to the housekeeping 
gene β-actin 100 000 × 2-ΔCT, and presented as mean ± SEM. * p≤0.05; ** p≤0.01. 
COMMENTS 
AR and HNSCC patients were characterized by distinct immunological reactions. 
HNSCC exhibited a dominant innate immune response with suppressed T cells, whereas 
the AR immune reactions were of an adaptive character with enhanced T cell activity.  
Previous reports regarding the association between allergy and cancer are inconsistent. 
This might partly be related to variations between tissues. Allergies occur primarily at 
body surfaces and for that reason the relation to cancer should be made to tumors with a 
corresponding location (14, 15). AR and HNSCC are both diseases with a systemic 
inflammatory component that affect the upper airway. In the present study HNSCC 
patients were sampled upon detection of their disease prior to initiation of treatment. This 
is often when the tumor disease is most active. For the same reason, the allergic 
individuals were sampled during pollen season.  
AR is a chronic lymphocyte mediated inflammatory condition traditionally characterized 
by increased Th2 activity (94). Generally, chronic inflammation is thought to constitute a 
risk factor for the development of cancer (73, 74), and cancer is also thought to have a 
dominating Th2 component that suppresses the anti-tumorigenic response of the 
adaptive immune system (95, 96). Therefore, it was interesting to find that HNSCC is 
characterized by an innate immune reaction with suppressed T cells, while allergy was 
confirmed to be a lymphocyte mediated inflammatory disease. However, the finding of 
both Th1 and Th2 cytokines in sera and PBMC culture supernatants of AR patients 
supports recent ideas that allergy is a complex disease, and not only characterized by an 
imbalance in the Th1 and Th2 activity (97). Therefore, the perspective that the Th2 
dominated reaction in allergy would suppress the Th1 response, and thereby inhibit the 
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anti-tumor immunity does not seem to hold true. A strong adaptive response is a 
prerequisite for a proper defense against tumors. Consequently, the enhanced adaptive 
immune response that was found in the allergic individuals might rather have a protective 
role against development of HNSCC. This also further emphasized that the nature of the 
immune response evoked will determine the efficacy of the tumor defense. 
In addition to the differences in the immune responses of circulating leukocytes, disparity 
was also found for the Nod2 expression between nasal epithelial cells from AR patients 
and HNSCC cells. We have previously reported that a reduced expression of Nod1 was 
detected in nasal biopsies from patients with ongoing allergy compared to controls (98), 
whereas we showed that there is a tendency towards an increased Nod1 expression in 
HNSCC biopsies compared to nasal biopsies from healthy controls (PAPER II). However, 
no real comparison can be made between these two studies since mRNA was assed with 
primers in the AR study and probes in the HNSCC investigation. Taken together, this 
suggests a distinguishing role of NLRs in airway allergy and cancer. It also further stresses 
that there may not only be systemic differences between these two diseases, but local 
disparities as well. 
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SUMMARY AND CONCLUSIONS 
- HNSCC cells exhibited a more marked expression of TLR2, TLR3, and TLR5 
than normal cells. Stimulation of Detroit-562, an epithelium derived cancer cell 
line, with TLR2, TLR3, and TLR5 agonists resulted in an up-regulation of ICAM-
1, increased secretion of IL-1β, IL-6 and IL-8, and decreased viability. In addition, 
the activation of TLR3 also affected the migratory behavior of the cancer cells. 
The non-tumorigenic cell line NL-20 and the primary HNEC did not display the 
same robust inflammatory response and cell death as the cancer cells did. This 
suggests a dual action of the TLR agonists in HNSCC – as immune stimulators 
and as apoptosis inducers. It also emphasizes the TLR system as an important 
target in future anti-tumor immunotherapy.  
- The NLR expression in HNSCC cells differed from what was seen in healthy nasal 
epithelial cells. Nod1 and Naip were the only investigated NLRs that were 
consistently expressed in the airway epithelial cells, and since there are no ligands 
available for Naip, only Nod1 could be functionally assessed. Like the expression, 
the functional response to Nod1 stimulation in HNSCC was found to differ from 
the reactions obtained in normal epithelial cells. Nod1 increased the production of 
β-defensin 2, GM-CSF, and G-CSF, and up-regulated ICAM-1 in malignant cells, 
with no corresponding response in normal cells. This indicates that Nod1 has the 
ability to enhance the migration of immunosuppressive myeloid cells into the 
tumor. If so, it implies that airway bacterial infections might enhance the tumor-
induced inflammation that in turn may have immunosuppressive properties.  
- HNSCC patients displayed an increased amount of total leukocytes, neutrophils, 
and monocytes, and a higher neutrophil/lymphocyte ratio than control subjects. 
An enhanced percentage of activated T cell subsets and NK cells, as determined 
by an elevated CD69, CD71, and CD98 expression was also observed among the 
cancer patients. In addition, CD14high CD16+ monocytes, and neutrophils from 
HNSCC patients displayed a low expression of CD62L. A high activation 
frequency of total T cells, Th cells, NK cells, and monocyte populations could be 
correlated with a more severe disease. Further, the neutrophil/lymphocyte ratio 
and the activation state of neutrophils, CD14high CD16+ monocytes, and Th cells 
at the time of cancer diagnosis could be linked to the life expectancy. The 
increased systemic inflammation seen among HNSCC patients signifies a 
connection between the immune phenotype, the anti-tumor immune response, 
and the survival of the patient. 
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- Three different neutrophil subsets characterized as CD16dim CD62Lhigh, CD16high 
CD62Lhigh, and CD16high CD62Ldim, were identified in the blood from HNSCC 
patients. The number of CD16dim CD62Lhigh cells was more pronounced among 
the cancer patients than the controls, and the cancer patients could be divided into 
two groups. Patients with a high percentage of CD16high CD62Ldim neutrophils 
seemed to have a better survival than those with a more normal level. It is also 
worth noticing that CD16high CD62Ldim neutrophils constitute a specific phenotype 
characterized by high CD11b and CD18 expression, and low IL-8 production. The 
CD16high CD62Ldim cells were also found to be more prone to migrate than the 
other neutrophils, and IL-8 appeared to be involved in the transformation of 
neutrophils into CD16high CD62Ldim cells. The three neutrophil subgroups 
appeared to correlate to specific variations in the cellular activation. Patients with a 
high amount of CD16high CD62Ldim cells in the circulation also seemed to have 
more neutrophils migrating into the tumor, and thereby benefiting from a more 
marked anti-tumorigenic immune response.    
- Patients with AR showed a general trend towards an increase in Th1 and Th2 
cytokines in serum. The same phenomenon was seen in supernatants from 
cultured PBMC. This signifies an adaptive immune reaction. The corresponding 
trend in HNSCC patients was dominated by innate immune cytokines like IL-1β, 
IL-17, MCP-1, MIP-1β, and G-CSF. PMN isolated from cancer patients showed a 
generally increased basal activation. These PMN also responded strongly to TLR 
stimulation by up-regulating the expression of CD11b, CD69, and increasing the 
secretion of IL-8. Hence, upper airway allergy and cancer seems to depict two 
distinct immunological events. The tumorigenic immune response is dominated by 
an innate immune reaction, and by suppressed T cells, whereas the allergic 
immune reaction is of a more adaptive nature characterized by an enhanced T cell 
activation. It is therefore tempting to propose that the enhanced systemic adaptive 
immune response seen among patients with AR might protect against 
development of HNSCC 
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FUTURE PERSPECTIVES 
TLRs are located at the cell surface and in endosomes, whereas NLRs are found in the 
cytosol. The different locations make it tempting to assume that these receptors 
complement each other to ensure an effective clearance of pathogens. In this thesis, we 
show that TLRs and NLRs cause separate immunological reactions in HNSCC. In 
addition, concomitant activation of these two receptor families did not induce any 
synergistic response in HNSCC cells (unpublished observation). 
In PAPER I, it was described that TLR stimulation can induce apoptosis of HNSCC cells 
and increase inflammation by secretion of cytokines like IL-8. In PAPER IV, it was shown 
that an elevated amount of CD16high CD62Ldim neutrophils can predict better survival of 
patients with HNSCC. Altogether the presented data makes it tempting to speculate in a 
connection between TLR induced increase in IL-8 and an enhancement of CD16high 
CD62Ldim neutrophils in blood and tumors. If such a relation exists it would strongly 
support the idea of anti-tumorigenic effects of TLR stimulation.  
TLRs have been shown to possess an ability to generate anti-tumorigenic activities in 
many forms of cancer. Ligands of this receptor family are presently undergoing clinical 
investigations for their immunostimulatory effects as adjuvants in vaccines (38, 99). The 
wide spread activation associated with these receptors, including their potential effect on 
tumor cells, makes it necessary to proceed with caution when implementing these drugs 
for therapeutic use. Hence, activation of the TLR system in cancer cells can cause both 
anti- and pro-tumorigenic responses (26, 100).  
The role of neutrophil migration and activation in cancer inflammation was evaluated in 
PAPERS III-V. We found that the tumor influences the activation of neutrophils (PAPER V). 
This finding was not surprising since HNSCC tumors are known to dictate the immune 
reaction in its favor (101). Nevertheless, in PAPER IV we showed that a high percentage of 
activated CD16high CD62Ldim neutrophils correlated with a better survival. If a favorable 
neutrophil phenotype is the result of an inborn ability to muster an innate immune 
response by the host or if this relates to the characteristics of the tumor per se remains to 
be evaluated.  
It is well known that the adaptive branch of the immune system is needed to launch a 
correct anti-tumorigenic immune reaction. However, the present studies show that innate 
immune responses seem to be equally important for the host, by causing neutrophil 
activation and migration. Even though the innate immunity is dominant in HNSCC, it is 
important to acknowledge the complexity of the immune system. The immune system 
should not be looked upon as two different compartments in the immunological reaction, 
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but rather be regarded as an interlaced system. The right proportion of activation of the 
different parts of the immune system is probably the best defense against tumors.  
Tumor biopsies from HNSCC patients displayed a higher Nod2 mRNA expression than 
nasal biopsies from both healthy controls and rhinitis patients outside and during pollen 
season. This suggests a strong local component of the PRR system in cancer to add to the 
more extensively evaluated systemic differences between allergic and cancer 
inflammation. Further, this raises questions about what other local inflammatory 
differences could be found in the mucosa of AR patients and HNSCC tumors. 
The thesis highlights the importance of a more thorough immunologic characterization of 
HNSCC. Such endeavors would not only increase the prognostic capacity, but also open 
up for individualized interventions in order to create a more favorable form of cancer 
inflammation. In this context it would be especially interesting to explore the anti-
tumorigenic effects of CD16high CD62Ldim neutrophils, and its benefits for the survival of 
patients with HNSCC.  
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